Know Cancer

or
forgot password

An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment


Phase 2
18 Years
N/A
Not Enrolling
Both
Stage IV NSCLC

Thank you

Trial Information

An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment


Inclusion Criteria:



- confirmed (within last 3 months)progressive Stage IV NSCLC

- estimated life span of 3 months

- phase angle of at least 5 as measured by bioimpedance

Exclusion Criteria:

- currently taking a lipid lowering medications

- has an imminently life threatening condition

- has pre-existing liver disease

- known allergy to soybeans

- uncontrolled diabetes or uncontrolled disturbance of lipid metabolism

- pregnant or lactating

- has a pacemaker or other implantable electronic medical device

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Survival

Outcome Time Frame:

from date of enrollment until date of death from any cause assessed up to 12 months

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

KLT-NSCLC-004

NCT ID:

NCT01640730

Start Date:

May 2012

Completion Date:

Related Keywords:

  • Stage IV NSCLC
  • Carcinoma, Non-Small-Cell Lung

Name

Location

The West ClinicMemphis, Tennessee  38120